Lupin Limited (LUPIN) — base & breakout chart
Healthcare · PharmaceuticalsStock page
Where it stands
- Stage
- Played out
- Pivot
- ₹2,312.00
- Price
- ₹2,062.00
- RS
- 27
10.8% to go±25%
Sessions since 430Turnover ₹167 Cras of 28 Sept 2026
Trend
- Above 50-day: no
- Above 150-day: no
- Above 200-day: no
- 150-day over 200-day: yes
- Trend template met: no
Delivery 64% this week vs 60% over the month35 analysts cover it — consensus hold
Price chart with bases
1st base on record. The latest cleared its ₹2,312.00 pivot on 31 Dec 2024.
Price chart of LUPIN, 493 daily bars from 2024-09-30 to 2026-09-28, with 1 bases shaded. Every base is listed in the table below.
Base history
Every base the detector recorded for this stock, newest first. Select one to highlight it on the chart.
| Base | Formed | Base age | Depth | Pivot | Contractions | Squats / pokes | Outcome |
|---|---|---|---|---|---|---|---|
| 5 Sept 2024 – 30 Dec 2024 | 16w | 14.1% | ₹2,312.00 | 2(last 5.7%) | 1 / 1 | Broke out31 Dec 2024 on 3.4× volHigh since 2020 |
What this chart shows
Lupin Limited (LUPIN) broke out of its latest base on 31 Dec 2024 (430 trading sessions ago), but has since slipped back below that base's ceiling. That base ran from 5 Sep 2024 to 30 Dec 2024, about 16 weeks. Its ceiling — the highest price inside the base, which traders call the pivot — was ₹2,312.00. On the breakout day it closed at ₹2,355.70, on trading volume 3.4 times its average daily volume during the base. The last close on 28 Sep 2026 was ₹2,062.00, 10.8% below the ceiling. A close back under the ceiling means that breakout did not hold. From its highest point to its lowest, the base is 14.1% deep. Inside it the price has pulled back two times, each pullback shallower than the one before. The ceiling is also the highest price LUPIN has reached since 2020, which is as far back as our price history goes. In our four-stage lifecycle it is currently "played out": broke out earlier but has since fallen back below its ceiling.
Its relative strength reading is 27 out of 99. That means its price over the past year has done better than about 27% of the 940 stocks we rank. It is a comparison with other stocks, not a forecast. Among the 71 Pharmaceuticals & Biotechnology stocks we track, it ranks 65 of 71 by that reading. The last close is below its 50-day, 150-day and 200-day averages — the average closing price over the last 50, 150 and 200 trading sessions, which people use to judge the longer trend. The 150-day average is itself above the 200-day average.
Since our base records begin (April 2024), we have found one base in LUPIN. It broke out above its ceiling. Today's price is below that breakout-day close.
How to read this page: a base is a stretch of weeks or months in which a stock stops trending and moves sideways within a range. The top of that range is its ceiling, which traders call the pivot; a close above it is what we count as a breakout. Relative strength compares a stock's price performance over the past year with every other stock we track, on a scale of 1 to 99. All of this describes what the price has already done. It is not a recommendation to buy or sell, and it does not predict what the price will do next. Our price history begins in 2020, so any "high" on this page means the highest price since 2020.
How to read it
- Shaded box — a base: the stretch where the stock stopped trending and traded sideways, from its high (the pivot) down to its lowest low.
- Line at the top of the box — the pivot, the price a close has to clear for the base to resolve upward. It runs on to the breakout, or to today for a base still forming.
- Arrow under a candle — the breakout day, with that day's volume as a multiple of the base's own average.
- P and S — a failed poke (traded above the pivot but closed back under it) and a squat (closed just under the pivot on light volume).
Prices are adjusted for splits and bonuses. Our price history starts in 2020, so any high mentioned here is a high since 2020, not an all-time high. Base detection describes past price and volume; it is for research and education, is not investment advice, and no pattern predicts future returns.